US drug maker resisted changes to its opioid dosing recommendations to protect revenue, newspaper allegesBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2683 (Published 11 May 2016) Cite this as: BMJ 2016;353:i2683
- Michael McCarthy
The drug manufacturer Purdue Pharmaceuticals resisted efforts to change the dosing recommendations for its long acting opioid OxyContin to protect its revenues, the Los Angeles Times has alleged in an investigative report published on 5 May.1
The company, however, has strongly rejected the paper’s claims. “In an attempt to resurrect a long-discredited theory, the paper ignores the clinical and regulatory data that directly contradicts their story,” Purdue said in a statement.
The report stated that Purdue …